Ethris GmbH
5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Dec 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Sep 10, 2027The maintenance fee for Conjugate with Target-Finding Ligand and Use Thereof (US 10,583,195) comes due Sep 10, 2027. Unpaid by Mar 10, 2028, it lapses early.
- 1 fee due Nov 14, 2027The maintenance fee for Minimal UTR sequences (US 11,981,910) comes due Nov 14, 2027. Unpaid by May 15, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 24, 2026
- Nov 17 US 12,799,493 Plasmid Containing a Sequence Encoding an Mrna with a Segmented Poly(A) Tail
- Sep 8 US 12,728,151 Treatment of Ciliopathies
- 2 terms have ended since Aug 24, 2026
- Oct 28 US 8,871,230 Conjugate with Target-Finding Ligand and Use Thereof · lapsed on the fee record
- Sep 25 US 10,080,804 Conjugate with Target-Finding Ligand and Use Thereof · lapsed on the fee record
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,555,122 | Conjugate with Target-Finding Ligand and Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 10,583,195 | Conjugate with Target-Finding Ligand and Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 10,745,698 | RNA with a combination of unmodified and modified nucleotides for protein expression In force · USPTO record | In force | USPTO record | |
| US 11,090,264 | Pulmonary Delivery of Mrna to Non-Lung Target Cells In force · High confidence | In force | High confidence | |
| US 12,064,484 | Compositions for introducing RNA into cells In force · USPTO record | In force | USPTO record | |
| US 10,272,161 | RNA for Use in the Treatment of Ligament or Tendon Lesions In force · High confidence | In force | High confidence | |
| US 11,065,346 | RNA for use in the treatment of ligament or tendon lesions In force · USPTO record | In force | USPTO record | |
| US 12,263,229 | Induction of osteogenesis by delivering BMP encoding RNA In force · USPTO record | In force | USPTO record | |
| US 12,594,295 | CFTR Mrna Compositions and Related Methods and Uses In force · Medium confidence | In force | Medium confidence | |
| US 11,479,768 | ATP-binding cassette family coding polyribonucleotides and formulations thereof In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 21: 5 patents in force now held by others · 3 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 1 abandoned · 9 no status recorded
Rows 11 to 14 of 14 are for members. The first 10 are on the company page.
Pro members see all 14 published applications.